Lipocine (LPCN) received revised regulatory guidance for LPCN 1154 which the company is developing for postpartum depression treatment. The company was scheduled to meet with the FDA in Q1 2025 to discuss the NDA submission package of LPCN 1154. Following the meeting, the company was advised that the Division believes, in addition to the previously completed PK bridge data, an efficacy and safety study of oral LPCN 1154 in the target population will be required for 505(b) NDA submission. Lipocine is planning next steps toward the execution of a phase 3 safety and efficacy study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue